Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Innovent Biologics

Explore full profile

Innovent Biologics is a biopharmaceutical company developing and manufacturing monoclonal antibodies

Suzhou Shi, ChinaFounded 2011Biotech & Life Sciences
Valuation $16B Market cap · Aug/2026
Revenue $2.55B Latest reported FY
EBITDA $371M Latest reported FY

At a glance

Founded
2011
Headquarters
Suzhou Shi, China
Listing
IPO 2018
Sector
Biotech & Life Sciences
Power Law
Decacorn$10B+ valuation tierThoroughbred$100M+ revenue

Research & analysis

From the Dealroom knowledge graph
News OPKO Health draws $125M against mazdutide royalties in KKR-linked deal Aug 14, 2026 News Spero secures $105M non-dilutive deal to fund immune-disease drug Jul 14, 2026 News Innovent Biologics secures up to $10.5B Pfizer oncology deal May 29, 2026

Latest news

Press, funding announcements and product moves mentioning Innovent Biologics.

See all news

Investors

20 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A1 investor entered at this stage

Series B and later19 investors entered at this stage

Talent

Book a demo to see the people
Founders Hidden — book a demo/100 quality score
Key operators Hidden — book a demo quality score
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
9 countries with
team presence
🇨🇳 China88.3%
🇺🇸 United States7.8%
🇭🇰 Hong Kong1.5%
🇸🇬 Singapore0.9%
🇬🇧 United Kingdom0.5%
Top 5 of 9 shown
Web traffic by country
20K monthly visits
across markets
🇺🇸 United States37.5%
🇭🇰 Hong Kong17%
🏳️ Korea10.5%
🏳️ Republic of8%
🇯🇵 Japan6.5%
Top 5 markets shown

Patents

Estimated portfolio value
$84M

151 active patent families included in this estimate.

A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.

Explore the patent portfolioPatent records, technology areas and peer comparisonsBook a demo

Investments and acquisitions

Disclosed deals where Innovent Biologics was the backer or acquirer, 2021–2024. Toggle between venture rounds, M&A, or both. The map below is grouped by the target company's sector — the colored pill on each chip is the round type.

Portfolio analysis

2 deals across Innovent Biologics's capital deployment.

Where the deals concentrate by sector, stage, and decade.

By sectorCount
    By stageCount
      By periodCount

        Innovent Biologics's portfolio, mapped.

        Each chip is one company. Pill colour shows round type — green for Seed, blue for Series A, purple for B/C+, pink for late-stage, amber for M&A. Bigger sectors keep their full list behind “+ N more”.

        Stage
        Period
        2 of 2 deals

        Market sentiment

        Posts on X, past 7 days

        An AI-synthesised read of the highest-engagement posts about Innovent Biologics on X, ranked by likes and reposts, corporate channels excluded.

        Reading the room on X — pulling top posts and synthesizing themes…

        Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

        See Innovent Biologics on the full Dealroom platform

        Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

        Book a demo Explore company profiles